Locally Advanced CancerRI-LieFNCT07529314
Evaluating Interventional Radiology for Cancer Pain Management
A study testing Self-reported questionnaires in people with Locally Advanced Cancer and Metastatic Cancer, run by Hospices Civils de Lyon.
Trial summary
Each year, the number of new cancer cases increases globally and the associated pain remains a major concern. The scientific literature shows that the prevalence and severity of cancer-related pain have decreased thanks to new therapeutic strategies and the efficacy of innovative treatments. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Locally Advanced Cancer, Metastatic Cancer
- What is being tested?
- Self-reported questionnaires
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 125 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 1 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patient (age > 18 years);
- Patient with locally advanced or metastatic cancer undergoing active management, including palliative care;
- Patient with a clinically estimated life expectancy of at least 3 months;
- Patient receiving treatment with chemotherapy, immunotherapy, targeted therapy, hormone therapy, or any other type of treatment for locally advanced or metastatic cancer;
- Patient undergoing an interventional radiology procedure for pain relief (including cases where pain relief is not the primary objective);
- Patient able to complete the proposed questionnaires.
Who cannot join
- Patient with cancer in remission;
- Patient with cured cancer;
- Patient under routine follow-up.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Evaluation of the Efficacy of Interventional Radiology in the Management of Pain in Patients With Cancer
Each year, the number of new cancer cases increases globally and the associated pain remains a major concern. The scientific literature shows that the prevalence and severity of cancer-related pain have decreased thanks to new therapeutic strategies and the efficacy of innovative treatments. Nevertheless, recent studies indicate that the prevalence of pain in patients with locally advanced or metastatic cancer remains high.
Cancer-related pain presents various characteristics, both in terms of timing (inflammatory and mechanical) and types (nociceptive, neuropathic, mixed, or visceral). This diversity in presentation and pathophysiology makes the condition complex, both in terms of symptom assessment and therapeutic management, requiring a multidisciplinary and often multimodal approach.
Read more
In addition to pharmacological approaches, several non-pharmacological techniques are used for this purpose, as the interventional radiology (IR), so-called minimally invasive technique. The role of IR is becoming increasingly important in pain management, particularly in the context of a growing number of cancer survivors, improved survival in the metastatic setting and the limited effectiveness of opioids. These techniques include neurolysis, embolization, consolidation techniques, ablation, and percutaneous cervical cordotomy.
The objective of the RI-Lief study is to evaluate the impact of interventional radiology on improving the quality of life of patients with locally advanced or metastatic cancer.
As part of the study, interventional radiology will be included in the standard patient care. The only additional procedure introduced by the research is the administration of questionnaires.
- Conditions
- Locally Advanced Cancer, Metastatic Cancer
- Being tested
- Self-reported questionnaires
- Keywords
- Cancer, Pain
- Medical subject headings
- Neoplasm Metastasis, Neoplasms, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Self-reported questionnairesOther
Self-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life (EORTC QLQ-C30 questionnaire)
| Study group | Role | What they receive |
|---|---|---|
| Self-reported questionnaires | Other | Self-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life : EORTC QLQ-C30 questionnaire ( (European Organisation for Research and Treatment of Cancer (EORTC); Quality of Life Questionnaire (QLQ) Core30 (C30)) Receives: Other: Self-reported questionnaires |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in pain intensity measured on a numerical scale before the interventional radiology procedure, and at 7 days, 1 month, and 3 months afterward.
To evaluate the efficacy of interventional radiology for pain relief in improving pain intensity in patients with locally advanced or metastatic cancer.
Measured: Baseline, 7 days, 1 month and 3 months after the radiology intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Sep 2028 (estimated)
- Study completion1 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Locally Advanced CancerStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 125 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07529314
- Sponsor's protocol ID
- 69HCL25_1073
- Acronym
- RI-LieF
- Status last verified
- Apr 2026
- First submitted
- 2 Apr 2026
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Efficacy of Interventional Radiology in the Management of Pain in Patients With Cancer
- ClinicalTrials.gov ID
- NCT07529314
- Acronym / sponsor ID
- RI-LieF / 69HCL25_1073
- Conditions
- Locally Advanced Cancer, Metastatic Cancer
- Keywords
- Cancer, Pain
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 125 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 Sep 2028 (estimated)
- Study completion
- 1 Sep 2028 (estimated)
- First posted
- 14 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Each year, the number of new cancer cases increases globally and the associated pain remains a major concern. The scientific literature shows that the prevalence and severity of cancer-related pain have decreased thanks to new therapeutic strategies and the efficacy of innovative treatments. Nevertheless, recent studies indicate that the prevalence of pain in patients with locally advanced or metastatic cancer remains high.
Cancer-related pain presents various characteristics, both in terms of timing (inflammatory and mechanical) and types (nociceptive, neuropathic, mixed, or visceral). This diversity in presentation and pathophysiology makes the condition complex, both in terms of symptom assessment and therapeutic management, requiring a multidisciplinary and often multimodal approach.
In addition to pharmacological approaches, several non-pharmacological techniques are used for this purpose, as the interventional radiology (IR), so-called minimally invasive technique. The role of IR is becoming increasingly important in pain management, particularly in the context of a growing number of cancer survivors, improved survival in the metastatic setting and the limited effectiveness of opioids. These techniques include neurolysis, embolization, consolidation techniques, ablation, and percutaneous cervical cordotomy.
The objective of the RI-Lief study is to evaluate the impact of interventional radiology on improving the quality of life of patients with locally advanced or metastatic cancer.
As part of the study, interventional radiology will be included in the standard patient care. The only additional procedure introduced by the research is the administration of questionnaires.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Self-reported questionnaires | Other | Other: Self-reported questionnairesSelf-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life : EORTC QLQ-C30 questionnaire ( (European Organisation for Research and Treatment of Cancer (EORTC); Quality of Life Questionnaire (QLQ) Core30 (C30)) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adult patient (age > 18 years);
- Patient with locally advanced or metastatic cancer undergoing active management, including palliative care;
- Patient with a clinically estimated life expectancy of at least 3 months;
- Patient receiving treatment with chemotherapy, immunotherapy, targeted therapy, hormone therapy, or any other type of treatment for locally advanced or metastatic cancer;
- Patient undergoing an interventional radiology procedure for pain relief (including cases where pain relief is not the primary objective);
Key exclusion criteria (3 listed)
- Patient with cancer in remission;
- Patient with cured cancer;
- Patient under routine follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Self-reported questionnairesSelf-reported questionnaires will be used to assess the patient's pain (using a Numerical Rating Scale and Neuropathic Pain Symptom Inventory), satisfaction with pain management (Pain Treatment Satisfactory Scale) and the global quality of life (EORTC QLQ-C30 questionnaire) | Other | Self-reported questionnaires |
Primary outcome
Difference in pain intensity measured on a numerical scale before the interventional radiology procedure, and at 7 days, 1 month, and 3 months afterward.
Time frame: Baseline, 7 days, 1 month and 3 months after the radiology intervention.
To evaluate the efficacy of interventional radiology for pain relief in improving pain intensity in patients with locally advanced or metastatic cancer.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2026.
Related trials for Locally Advanced Cancer
Not yet recruitingPhase 1
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
Advanced or Metastatic Breast Cancer
RecruitingPhase 2
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Differentiated Thyroid Carcinoma
Not yet recruitingPhase 1
DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer
Bladder Cancer
RecruitingPhase 1
HER2 Vaccine for Locally Advanced Breast Cancer
Breast Cancer, HER2-positive Breast Cancer
RecruitingPhase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Self-reported questionnaires in people with Locally Advanced Cancer and Metastatic Cancer, run by Hospices Civils de Lyon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Guillaume ECONOMOS (04.78.86.10.99, guillaume.economos@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in pain intensity measured on a numerical scale before the interventional radiology procedure, and at 7 days, 1 month, and 3 months afterward. (time frame: Baseline, 7 days, 1 month and 3 months after the radiology intervention.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.